<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2010-09-14" updated="2019-12-02">
  <drugbank-id primary="true">DB06760</drugbank-id>
  <name>Sacrosidase</name>
  <description>Sacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and children. Treatment options for these patients are limited and usually consists of a lifelong sucrose-free diet; therefore, sacrosidase offers a potential alternative for symptom relief.</description>
  <cas-number/>
  <unii>8A7F670F2Y</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7040</ref-id>
        <pubmed-id>9932843</pubmed-id>
        <citation>Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J: Sacrosidase therapy for congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1999 Feb;28(2):137-42.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of congenital sucrose-isomaltase deficiency (CSID).</indication>
  <pharmacodynamics/>
  <mechanism-of-action>Sacrosidase is a [beta]-fructofuranoside fructohydrolase that hydrolyzes sucrose. Unlike human intestinal sucrase-isomaltase, it has no activity with oligosaccharides containing 1,6 glucosyl bonds.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption>It has been suggested that sucrose is better absorbed (and sacrosidase activity preserved) when patients were given milk before sacrosidase rather than consuming the enzyme product alone. Therefore, it has been recommended to take half dose of sacrosidase just after a protein-containing meal, and the other half of the dose approximately half-way through the meal.</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products>
    <product>
      <name>Sucraid</name>
      <labeller>QOL Medical, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>6787-1011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-16</started-marketing-on>
      <ended-marketing-on>2006-06-16</ended-marketing-on>
      <dosage-form>Solution, concentrate</dosage-form>
      <strength>8500 [iU]/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sucraid</name>
      <labeller>QOL Medical, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67871-111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-04-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>8500 [iU]/1mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA020772</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Sucraid</name>
      <ingredients>Sacrosidase</ingredients>
    </mixture>
    <mixture>
      <name>Sucraid</name>
      <ingredients>Sacrosidase</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Glycoside Hydrolases</category>
      <mesh-id>D006026</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Sucrose-specific Enzyme</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>8500 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution, concentrate</form>
      <route>Oral</route>
      <strength>8500 [iU]/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A16AB06">
      <level code="A16AB">Enzymes</level>
      <level code="A16A">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A16">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents>
    <patent>
      <number>9469847</number>
      <country>United States</country>
      <approved>2016-10-18</approved>
      <expires>2034-02-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9849161</number>
      <country>United States</country>
      <approved>2017-12-26</approved>
      <expires>2034-02-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9255261</number>
      <country>United States</country>
      <approved>2016-02-09</approved>
      <expires>2034-02-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910368</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D05782</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Sacrosidase</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1201487</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/sacrosidase.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>